FDA says Novartis gene therapy drug application contains manipulated data

On May 24, the FDA approved Zolgensma, a gene therapy product intended to treat children less than two years of age with spinal muscular atrophy, but was informed recently by the product ’s manufacturer about a data manipulation issue
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news